Nurix Therapeutics, Inc.

NRIX

$25.63

-0.23%-$0.06

High—

Low—

52W High-9.2%

Rel. vol—

Interval

Range2.7h

Volume—SMA5SMA10

—

AI analysis

Nurix Therapeutics, Inc. is showing mixed intraday momentum with consolidation near key moving averages and heightened sensitivity to liquidity shifts.

Upside confirmation strengthens on sustained reclaim above short-term trend anchors.
Breakdown risk rises if support fails with accelerating sell volume.
Relative strength versus sector peers remains neutral-to-slightly positive.

Latest indicator snapshot

Live technical and fundamental context, tuned for quick reads.

SMA5

$25.65

5-period simple moving average

SMA10

$25.65

10-period simple moving average

SMA20

$25.65

20-period simple moving average

SMA50

$25.64

50-period simple moving average

EMA5

$25.65

5-period exponential moving average

EMA10

$25.65

10-period exponential moving average

EMA20

$25.64

20-period exponential moving average

DEMA20

$25.65

Double exponential moving average

Fibonacci

Retracement

Retracement levels

VWAP

$25.59

Volume weighted average price

MACD

0.005

Signal 0.003

RSI(14)

47.1

Relative strength oscillator

OBV

136.90K

On-balance volume

StochRSI

47.1 / 47.1

Fast oscillator pair

BBands Low

$25.59

Lower band

BBands Mid

$25.65

Middle band

BBands High

$25.70

Upper band

Market Cap

2.63B

Company size

P/E Ratio

0.00

Valuation multiple

EV / EBITDA

-3.35

Enterprise value multiple

ROE

-80.3%

Return on equity

ROA

-40.1%

Return on assets

Operating Margin

-1042.0%

Operating efficiency

Net Margin

0.0%

Bottom-line profitability

Current Ratio

—

Short-term liquidity

Debt / Equity

—

Balance-sheet leverage

Dividend Yield

0.0%

Income yield

FCF Yield

—

Free cash flow yield

Beta

1.79

Market sensitivity

52W High

$28.23

52-week peak

52W Low

$8.20

52-week trough

Supply Chain of NRIX

Upstream / Downstream / Proxies

Upstream

Contract Manufacturing Organizations (Undisclosed Single-Source Providers)Contract Research Organizations (Undisclosed Oncology CROs)DNA-Encoded Library Reagent & Synthesis SuppliersSpecialty Chemical & Raw Material Suppliers

Downstream

Roche Holding AGSIX:ROGilead Sciences, Inc.NASDAQ:GILD Sanofi S.A.NASDAQ:SNY Pfizer Inc. (via Seagen acquisition)NYSE:PFEClinical Trial Sites & Investigators

Proxies

Arvinas, Inc.NASDAQ:ARVN Kymera Therapeutics, Inc.NASDAQ:KYMR C4 Therapeutics, Inc.NASDAQ:CCCC Monte Rosa Therapeutics, Inc.NASDAQ:GLUE

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer